-
1.发明授权Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer 有权吲唑基，苯并咪唑基，苯并三唑基取代的二氢吲哚酮衍生物作为可用于治疗癌症的激酶抑制剂公开(公告)号：US08765748B2
公开(公告)日：2014-07-01
申请号：US12808961
申请日：2008-12-19
申请人： Heinz W. Pauls , Bryan T. Forrest , Radoslaw Laufer , Miklos Feher , Peter Brent Sampson , Guohua Pan , Sze-Wan Li , Yong Liu
发明人： Heinz W. Pauls , Bryan T. Forrest , Radoslaw Laufer , Miklos Feher , Peter Brent Sampson , Guohua Pan , Sze-Wan Li , Yong Liu
IPC分类号： A61P35/00 , A61P35/02 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/10 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , A61K31/416 , A61K31/4192 , A61K31/4184 , A61K31/4439 , A61K31/496 , A61K31/437 , A61K31/5377
CPC分类号： C07D403/06 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及由结构式（A）表示的化合物或其药学上可接受的盐。 本发明还涉及包含由上述结构式（A）表示的化合物或其药学上可接受的盐和药学上可接受的载体或稀释剂的药物组合物。 还公开了治疗患有癌症的受试者的方法，其中所述方法包括施用治疗有效量的由上述结构式（A）表示的化合物或其药学上可接受的盐。
-
2.发明授权公开(公告)号：US08680282B2
公开(公告)日：2014-03-25
申请号：US12671154
申请日：2008-08-01
申请人： Heinz W. Pauls , Bryan T. Forrest , Peter Brent Sampson , Yong Liu , Radoslaw Laufer , Yunhui Lang , Miklos Feher , Yi Yao , Guohua Pan
发明人： Heinz W. Pauls , Bryan T. Forrest , Peter Brent Sampson , Yong Liu , Radoslaw Laufer , Yunhui Lang , Miklos Feher , Yi Yao , Guohua Pan
IPC分类号： C07D211/58 , A61K31/4468
CPC分类号： C07D211/58 , C07C275/36 , C07D205/04 , C07D207/09 , C07D211/56 , C07D405/12
摘要： A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译： CPT1抑制剂化合物由结构式（I）或其药学上可接受的盐表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗患有癌症的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。
-
3.发明申请INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER 有权CARNITINE PALMITOYLTRANSFERASE和治疗癌症的抑制剂公开(公告)号：US20100105900A1
公开(公告)日：2010-04-29
申请号：US12530429
申请日：2008-03-09
申请人： Heinz W. Pauls , Peter Brent Sampson , Bryan T. Forrest , Radoslaw Laufer , Yong Liu , Miklos Feher , Yi Yao , Guohua Pan
发明人： Heinz W. Pauls , Peter Brent Sampson , Bryan T. Forrest , Radoslaw Laufer , Yong Liu , Miklos Feher , Yi Yao , Guohua Pan
IPC分类号： C07D295/18 , C07D307/02 , C07D333/22 , C07C229/00 , C07D239/02 , C07D213/78 , C07D417/04
CPC分类号： C07D409/06 , C07C1/26 , C07C17/10 , C07C2529/40 , C07D207/325 , C07D213/71 , C07D213/82 , C07D231/12 , C07D231/14 , C07D263/34 , C07D277/48 , C07D295/215 , C07D307/24 , C07D307/68 , C07D307/82 , C07D333/34 , C07D333/40 , C07D401/04 , C07D405/06 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07C9/00 , C07C19/075
摘要： A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译： CPT抑制剂化合物由结构式（I）或其药学上可接受的盐表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗患有癌症的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。
-
公开(公告)号：US07648987B2
公开(公告)日：2010-01-19
申请号：US11633301
申请日：2006-12-04
申请人： Andrew Philip Crew , Han-Qing Dong , Mark Joseph Mulvihill , Douglas S. Werner , Mridula Kadalbajoo , Radoslaw Laufer
发明人： Andrew Philip Crew , Han-Qing Dong , Mark Joseph Mulvihill , Douglas S. Werner , Mridula Kadalbajoo , Radoslaw Laufer
IPC分类号： C07D471/06 , A61K31/4985
CPC分类号： C07D487/04
摘要： Compounds of the Formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
摘要翻译： 其中X1，X2，X3，X4，X5，X6，X7，R1和Q1在本文中定义的式及其药学上可接受的盐的化合物抑制蛋白激酶，并且可用于治疗和/或预防过度增殖性疾病 例如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统的疾病和状况，中枢神经系统的疾病和状况。
-
公开(公告)号：US08980934B2
公开(公告)日：2015-03-17
申请号：US13923982
申请日：2013-06-21
申请人： Heinz W. Pauls , Radoslaw Laufer , Sze-Wan Li , Grace Ng
发明人： Heinz W. Pauls , Radoslaw Laufer , Sze-Wan Li , Grace Ng
IPC分类号： A61K31/416 , C07D231/56 , C07D491/107 , C07D403/10 , C07D401/14 , C07D487/10 , C07D409/14
CPC分类号： C07D491/107 , C07D401/14 , C07D403/10 , C07D409/14 , C07D487/10
摘要： The present teachings provide a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
摘要翻译： 本发明提供由结构式（I）表示的化合物或其药学上可接受的盐。 还描述了药物组合物及其使用方法。
-
公开(公告)号：US08481533B2
公开(公告)日：2013-07-09
申请号：US13529542
申请日：2012-06-21
申请人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
发明人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
IPC分类号： A61K31/5377 , A61K31/416 , C07D273/01 , C07D231/54
CPC分类号： C07D403/10 , A61K31/5377 , A61K45/06 , C07D231/56 , C07D403/04 , C07D403/14 , C07D413/14
摘要： The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
-
7.发明授权公开(公告)号：US08101613B2
公开(公告)日：2012-01-24
申请号：US12540047
申请日：2009-08-12
申请人： Lee D. Arnold , Cara Cesario , Heather Coate , Andrew Philip Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Michelle Mulvihill , Mark J. Mulvihill , Anthony I. Nigro , Bijoy Panicker , Amo G. Steinig , Yingchuan Sun , Qinghua Weng , Douglas S. Werner , Michael J. Wyle , Tao Zhang
发明人： Lee D. Arnold , Cara Cesario , Heather Coate , Andrew Philip Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Michelle Mulvihill , Mark J. Mulvihill , Anthony I. Nigro , Bijoy Panicker , Amo G. Steinig , Yingchuan Sun , Qinghua Weng , Douglas S. Werner , Michael J. Wyle , Tao Zhang
IPC分类号： A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , C07D471/00 , C07D487/00
CPC分类号： C07F5/025 , C07D471/04 , C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
摘要翻译： 其中X 1，X 2，X 3，X 4，X 5，X 6，X 7，R 1和Q 1在本文中定义的式及其药学上可接受的盐的化合物抑制IGF-1R酶，并且可用于治疗和/或预防 过度增生性疾病如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统的疾病和状况，中枢神经系统的疾病和状况。
-
公开(公告)号：US20110263598A1
公开(公告)日：2011-10-27
申请号：US13081254
申请日：2011-04-06
申请人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
发明人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
IPC分类号： A61K31/5377 , A61P35/02 , A61K31/416 , A61P35/00 , C07D487/04 , C07D273/01
CPC分类号： C07D403/10 , A61K31/5377 , A61K45/06 , C07D231/56 , C07D403/04 , C07D403/14 , C07D413/14
摘要： The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
摘要翻译： 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。
-
公开(公告)号：US07767673B2
公开(公告)日：2010-08-03
申请号：US12209862
申请日：2008-09-12
申请人： Arlindo L. Castelhano , Andrew P. Crew , Han-Qing Dong , Radoslaw Laufer , An-Hu Li , Li Qiu , Colin Peter Sambrook Smith , Tao Zhang
发明人： Arlindo L. Castelhano , Andrew P. Crew , Han-Qing Dong , Radoslaw Laufer , An-Hu Li , Li Qiu , Colin Peter Sambrook Smith , Tao Zhang
IPC分类号： A61K31/5377 , C07D413/12
CPC分类号： C07D471/04
摘要： Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-Oxide thereof, are useful in the treatment of cancer.
摘要翻译： 由式（I）表示的化合物或其药学上可接受的盐或N-氧化物可用于治疗癌症。
-
10.发明申请公开(公告)号：US20090325928A1
公开(公告)日：2009-12-31
申请号：US12540047
申请日：2009-08-12
申请人： Lee D. Arnold , Heather Coate , Andrew Philip Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Michelle Mulvihill , Mark Joseph Mulvihill , Anthony Nigro , Bijoy Panicker , Arno G. Steinig , Qingua Weng , Douglas S. Werner , Michael J. Wyle , Tao Zhang , Cara Cesario , Yingchuan Sun
发明人： Lee D. Arnold , Heather Coate , Andrew Philip Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Michelle Mulvihill , Mark Joseph Mulvihill , Anthony Nigro , Bijoy Panicker , Arno G. Steinig , Qingua Weng , Douglas S. Werner , Michael J. Wyle , Tao Zhang , Cara Cesario , Yingchuan Sun
IPC分类号： C07D471/04 , A61K31/495 , A61K31/519 , A61K31/5377 , A61K31/551 , A61P35/04
CPC分类号： C07F5/025 , C07D471/04 , C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
摘要翻译： 其中X 1，X 2，X 3，X 4，X 5，X 6，X 7，R 1和Q 1在本文中定义的式及其药学上可接受的盐的化合物抑制IGF-1R酶，并且可用于治疗和/或预防 过度增生性疾病如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统的疾病和状况，中枢神经系统的疾病和状况。
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.05 秒)
